{"id":"https://openalex.org/W2885709677","doi":"https://doi.org/10.1158/1538-7445.am2018-4561","title":"Abstract 4561: Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody","display_name":"Abstract 4561: Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody","publication_year":2018,"publication_date":"2018-07-01","ids":{"openalex":"https://openalex.org/W2885709677","doi":"https://doi.org/10.1158/1538-7445.am2018-4561","mag":"2885709677"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2018-4561","doi":"https://doi.org/10.1158/1538-7445.am2018-4561","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-4561","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042586940","display_name":"Joanne B.L. Tan","orcid":"https://orcid.org/0000-0003-2860-6306","observed_orcids":["https://orcid.org/0000-0003-2860-6306"]},"institutions":[{"id":"https://openalex.org/I4405269550","display_name":"Arcus Biosciences (United States)","ror":"https://ror.org/04gs0mk80","country_code":"US","type":"company","lineage":["https://openalex.org/I4405269550"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanne B. Tan","raw_affiliation_strings":["1Arcus Bioscienes, Hayward, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Arcus Bioscienes, Hayward, CA;","institution_ids":["https://openalex.org/I4405269550"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Chris Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799321762","display_name":"WuXi AppTec (China)","ror":"https://ror.org/04eh3ca90","country_code":"CN","type":"company","lineage":["https://openalex.org/I2799321762"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Chris Chen","raw_affiliation_strings":["2Wuxi AppTec, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi AppTec, Shanghai, China;","institution_ids":["https://openalex.org/I2799321762"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kai Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kai Chen","raw_affiliation_strings":["3Harbin Gloria Pharmaceuticals, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Harbin Gloria Pharmaceuticals, Beijing, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007469028","display_name":"Guochun Li","orcid":"https://orcid.org/0000-0002-1680-130X","observed_orcids":["https://orcid.org/0000-0002-1680-130X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guochun Li","raw_affiliation_strings":["3Harbin Gloria Pharmaceuticals, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Harbin Gloria Pharmaceuticals, Beijing, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jing Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799321762","display_name":"WuXi AppTec (China)","ror":"https://ror.org/04eh3ca90","country_code":"CN","type":"company","lineage":["https://openalex.org/I2799321762"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jing Li","raw_affiliation_strings":["2Wuxi AppTec, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi AppTec, Shanghai, China;","institution_ids":["https://openalex.org/I2799321762"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101758005","display_name":"Jieying Liu","orcid":"https://orcid.org/0000-0001-9041-3834","observed_orcids":["https://orcid.org/0000-0001-9041-3834"]},"institutions":[{"id":"https://openalex.org/I2799321762","display_name":"WuXi AppTec (China)","ror":"https://ror.org/04eh3ca90","country_code":"CN","type":"company","lineage":["https://openalex.org/I2799321762"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jieying Liu","raw_affiliation_strings":["2Wuxi AppTec, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi AppTec, Shanghai, China;","institution_ids":["https://openalex.org/I2799321762"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088428359","display_name":"Hema Singh","orcid":"https://orcid.org/0009-0001-1694-5928","observed_orcids":["https://orcid.org/0009-0001-1694-5928"]},"institutions":[{"id":"https://openalex.org/I4405269550","display_name":"Arcus Biosciences (United States)","ror":"https://ror.org/04gs0mk80","country_code":"US","type":"company","lineage":["https://openalex.org/I4405269550"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hema Singh","raw_affiliation_strings":["1Arcus Bioscienes, Hayward, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Arcus Bioscienes, Hayward, CA;","institution_ids":["https://openalex.org/I4405269550"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007970751","display_name":"Guoyong Wang","orcid":"https://orcid.org/0000-0002-8224-7706","observed_orcids":["https://orcid.org/0000-0002-8224-7706"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guoyong Wang","raw_affiliation_strings":["3Harbin Gloria Pharmaceuticals, Beijing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Harbin Gloria Pharmaceuticals, Beijing, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050027442","display_name":"Baotian Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799321762","display_name":"WuXi AppTec (China)","ror":"https://ror.org/04eh3ca90","country_code":"CN","type":"company","lineage":["https://openalex.org/I2799321762"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Baotian Yang","raw_affiliation_strings":["2Wuxi AppTec, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi AppTec, Shanghai, China;","institution_ids":["https://openalex.org/I2799321762"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056176126","display_name":"Kristin Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405269550","display_name":"Arcus Biosciences (United States)","ror":"https://ror.org/04gs0mk80","country_code":"US","type":"company","lineage":["https://openalex.org/I4405269550"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristin Zhang","raw_affiliation_strings":["1Arcus Bioscienes, Hayward, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Arcus Bioscienes, Hayward, CA;","institution_ids":["https://openalex.org/I4405269550"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043691200","display_name":"Xiaoning Zhao","orcid":"https://orcid.org/0009-0005-4662-3339","observed_orcids":["https://orcid.org/0009-0005-4662-3339"]},"institutions":[{"id":"https://openalex.org/I4405269550","display_name":"Arcus Biosciences (United States)","ror":"https://ror.org/04gs0mk80","country_code":"US","type":"company","lineage":["https://openalex.org/I4405269550"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoning Zhao","raw_affiliation_strings":["1Arcus Bioscienes, Hayward, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Arcus Bioscienes, Hayward, CA;","institution_ids":["https://openalex.org/I4405269550"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111671086","display_name":"Yong Tang Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799321762","display_name":"WuXi AppTec (China)","ror":"https://ror.org/04eh3ca90","country_code":"CN","type":"company","lineage":["https://openalex.org/I2799321762"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yong Zheng","raw_affiliation_strings":["2Wuxi AppTec, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi AppTec, Shanghai, China;","institution_ids":["https://openalex.org/I2799321762"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"13_Supplement","first_page":"4561","last_page":"4561"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.9330000281333923},{"id":"https://openalex.org/keywords/pd-1-pd-l1-axis","display_name":"PD-1/PD-L1 axis","score":0.9549999833106995},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.703000009059906},{"id":"https://openalex.org/keywords/tumor-immune-evasion","display_name":"tumor immune evasion","score":0.5889999866485596},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.6840000152587891},{"id":"https://openalex.org/keywords/cynomolgus-monkey-pharmacokinetics","display_name":"cynomolgus monkey pharmacokinetics","score":0.8259999752044678},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.5410000085830688},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.4440000057220459},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.4390000104904175},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6570589542388916},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.6137145757675171},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5905181765556335},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5475172400474548},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4823562502861023},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4128928482532501},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.39696046710014343},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3764670789241791},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37645411491394043},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35006654262542725},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34723207354545593},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3363097906112671},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.26783397793769836}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2018-4561","doi":"https://doi.org/10.1158/1538-7445.am2018-4561","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-4561","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3201469590","https://openalex.org/W3029868931","https://openalex.org/W2904489658","https://openalex.org/W4231895300","https://openalex.org/W2399033183","https://openalex.org/W3134905109","https://openalex.org/W2236929991","https://openalex.org/W2740703372","https://openalex.org/W3083221077","https://openalex.org/W3081548758"],"abstract_inverted_index":{"Abstract":[0],"INTRODUCTION:":[1],"Exhausted":[2],"T":[3,292,307,386],"cells":[4],"express":[5],"high":[6],"levels":[7],"of":[8,26,44,61,99,126,164,208,216,229,237,254,285,336,351,371,385,392,443,455],"several":[9],"immune":[10,36,103],"checkpoint":[11],"proteins,":[12],"including":[13],"the":[14,24,27,41,79,217,227,230,244,349,369,456],"programmed":[15],"death-1":[16],"(PD-1)":[17],"receptor.":[18],"Preclinical":[19,441],"and":[20,66,74,84,92,107,116,158,167,224,249,257,264,267,288,342,348,361,377,405],"clinical":[21,410],"data":[22],"support":[23],"role":[25],"PD-1/PD-L1":[28],"axis":[29],"in":[30,55,138,151,304,325,389,400,412],"promoting":[31],"tumor":[32,135,323],"evasion":[33],"by":[34,88,290],"curtailing":[35],"responses.":[37],"We":[38],"present":[39],"here":[40],"preclinical":[42],"characterization":[43,442],"GLS-010":[45,62,100,127,147,171,209,238,315,337,356,444],"(AB122),":[46],"a":[47,132,152,174,282,332,359,390],"novel":[48,360],"fully":[49,175,447],"human":[50,65,142,176,183,372],"anti-PD-1":[51,450],"monoclonal":[52,178],"antibody":[53,179,365,451],"currently":[54],"Phase":[56],"1.":[57],"METHODS:":[58],"The":[59,123],"affinity":[60],"(AB122)":[63,101,128,148,172,210,239,316,338,357],"for":[64,72,141,459],"cynomolgus":[67,160,344],"monkey":[68],"PD-1,":[69,73],"its":[70,75,399,408],"specificity":[71,228],"ability":[76],"to":[77,156,182,212,240,340],"block":[78],"PD-1":[80,184,195,373],"interaction":[81,245,370],"with":[82,118,246,251,374,398],"PD-L1":[83,376],"PD-L2":[85],"were":[86,302,346],"measured":[87],"ELISA,":[89],"flow":[90,192,262],"cytometry":[91],"TCR-activated":[93],"reporter":[94,272],"gene":[95,273],"assays.":[96],"Functional":[97,232],"assessment":[98],"on":[102],"responses":[104],"(IFN-g,":[105],"IL-2,":[106],"proliferation)":[108],"was":[109,129,149,317,353],"performed":[110],"using":[111,131,312],"mixed":[112],"lymphocyte":[113],"reaction":[114],"(MLR)":[115],"re-stimulation":[117],"cytomegalovirus":[119],"(CMV)":[120],"pp665":[121],"peptide.":[122],"anti-tumor":[124],"efficacy":[125],"evaluated":[130],"mouse":[133,205],"MC-38":[134,322],"model":[136],"grown":[137],"mice":[139,404],"transgenic":[140,327],"PD-1.":[143,206],"For":[144],"PK":[145,329],"analysis,":[146],"given":[150],"single":[153,333],"i.v.":[154,334],"bolus":[155],"male":[157,341],"female":[159,343],"monkeys":[161,345],"at":[162,295,320],"doses":[163],"2,":[165],"6":[166],"18":[168],"mg/kg.":[169],"RESULTS:":[170],"is":[173,358],"IgG4":[177],"that":[180,235,366],"binds":[181],"(EC50":[185,196],"~":[186,197],"210":[187],"pM,":[188,191,199,259],"ELISA;":[189],"770":[190],"cytometry),":[193],"cyno":[194],"150":[198],"ELISA),":[200],"but":[201],"not":[202],"rat":[203],"or":[204],"Lack":[207],"binding":[211,236],"other":[213],"related":[214],"members":[215],"CD28":[218,223],"family,":[219],"such":[220],"as":[221],"ICOS,":[222],"CTLA-4,":[225],"confirms":[226],"interaction.":[231],"studies":[233],"showed":[234,281],"cell-expressed":[241],"hPD-1":[242,326],"inhibits":[243],"both":[247,375],"hPD-L1":[248],"hPD-L2":[250],"an":[252,305],"IC50":[253],"580":[255],"pM":[256],"670":[258],"respectively":[260,270],"(by":[261],"cytometry)":[263],"2.2":[265],"nM":[266],"5.8":[268],"nM,":[269],"(in":[271,403],"assay).":[274],"Using":[275],"allogeneic":[276],"monocyte-derived":[277],"dendritic":[278],"cells,":[279,293],"we":[280],"dose-dependent":[283],"enhancement":[284,384],"IFN-g":[286],"production":[287],"proliferation":[289],"CD4+":[291],"saturating":[294],"concentrations":[296],"below":[297],"100":[298],"pM.":[299],"Similar":[300],"results":[301],"obtained":[303],"antigen-specific":[306],"cell":[308,387,393],"recall":[309],"response":[310],"assay":[311],"CMV-infected":[313],"donors.":[314],"very":[318],"effective":[319],"blocking":[321],"growth":[324],"mice.":[328],"profiles":[330],"following":[331],"dose":[335],"administered":[339],"dose-proportional":[347],"rate":[350],"clearance":[352],"dose-independent.":[354],"CONCLUSIONS:":[355],"selective":[362],"antagonistic":[363],"anti-hPD-1":[364],"potently":[367],"blocks":[368],"PD-L2.":[378],"This":[379],"blockade":[380],"translates":[381],"into":[382],"potent":[383],"activation":[388],"variety":[391],"culture":[394],"studies,":[395],"which":[396],"combined":[397],"vivo":[401],"profile":[402],"monkeys)":[406],"supports":[407],"ongoing":[409],"development":[411],"oncology.":[413],"Citation":[414],"Format:":[415],"Joanne":[416],"B.":[417],"Tan,":[418],"Chris":[419],"Chen,":[420,422],"Kai":[421],"Guochun":[423],"Li,":[424,426],"Jing":[425],"Jieying":[427],"Liu,":[428],"Hema":[429],"Singh,":[430],"Guoyong":[431],"Wang,":[432],"Baotian":[433],"Yang,":[434],"Kristin":[435],"Zhang,":[436],"Xiaoning":[437],"Zhao,":[438],"Yong":[439],"Zheng.":[440],"(AB122):":[445],"A":[446],"humanized":[448],"clinical-stage":[449],"[abstract].":[452],"In:":[453],"Proceedings":[454],"American":[457],"Association":[458],"Cancer":[460,473],"Research":[461],"Annual":[462],"Meeting":[463],"2018;":[464],"2018":[465],"Apr":[466],"14-18;":[467],"Chicago,":[468],"IL.":[469],"Philadelphia":[470],"(PA):":[471],"AACR;":[472],"Res":[474],"2018;78(13":[475],"Suppl):Abstract":[476],"nr":[477],"4561.":[478]},"counts_by_year":[{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2018-08-22T00:00:00"}